Summary

In a single-site, retrospective study comparing the efficacy of several platinum doublet regimens in patients with EGFR wild-type, nonsquamous non–small cell lung cancer, no differences were found in overall survival or response rate between platinum plus pemetrexed or nonpemetrexed therapies (eg, gemcitabine, taxanes).